Patient Support Services Contact Us
Expanding Our Mission to Immuno-oncology
More choice without compromise

Building on our success with UDENYCA® (pegfilgrastim-cbqv), we are now expanding our mission to immuno-oncology with Junshi Biosciences’ novel anti-PD-1 antibody, toripalimab.

I-O Begins Here: Late-Stage Anti-PD-1 Antibody

Our foundational first step in immuno-oncology begins with Junshi Biosciences’ anti-PD-1 antibody.

Learn More

Expanded Mission. Expanded Pipeline.

Our expanded immuno-oncology pipeline will be funded with cash flows generated by our commercial biosimilar business.

Learn More

Latest News

Coherus BioSciences to Present at the Bank of America Health Care Conference

Learn More

Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress

Learn More

Coherus BioSciences Announces New Employment Inducement Grants

Learn More

Coherus Issues Statement of Support for Passage of Biosimilar Legislation

WASHINGTON, D.C., April 14, 2021 -- Coherus BioSciences, Inc.’s (“Coherus”, Nasdaq: CHRS), CEO Denny Lanfear today issued a public statement of support regarding the passage of the Advancing Education on Biosimilars Act of 2021 (S.164).

View Now